Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592575 | 0.94 | TSHR (0.38) | DUTALDH1A1TSHRLPAR3LMNA | |
| SCHEMBL30895945 | 0.92 | TSHR (0.41) | DUTALDH1A1TSHRLPAR3LMNA | |
| SCHEMBL17732227 | 0.92 | TSHR (0.41) | DUTALDH1A1TSHRLPAR3LMNA | |
| SCHEMBL1931760 | 0.92 | TSHR (0.41) | DUTALDH1A1TSHRLPAR3LMNA | |
| SCHEMBL2245848 | 0.92 | TSHR (0.41) | DUTALDH1A1TSHRLPAR3LMNA | |
| SCHEMBL4059577 | 0.86 | DUT (0.33) | DUTTSHR | |
| SCHEMBL2244296 | 0.85 | TSHR (0.36) | DUTALDH1A1TSHRLPAR3LMNA | |
| SCHEMBL27040101 | 0.83 | DUT (0.37) | DUT | |
| SCHEMBL28538333 | 0.81 | DUT (0.43) | DUT | |
| SCHEMBL8063404 | 0.81 | DUT (0.43) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| CN-115298176-A | Compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220071971-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-11220513-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-01-11 | — | — | US | disclosed |
| EP-3898621-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021190727-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| WO-2016176560-A1 | CHROMIUM-MEDIATED COUPLING AND APPLICATION TO THE SYNTHESIS OF HALICHONDRINS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20150309022-A1 | Synthetic Ligands for the Differentiation of Closely Related Toxins and Pathogens | UNIVERSITY OF CINCINNATI (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| WO-2015106045-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | PURDUE RESEARCH FOUNDATION (US) | 2015-07-16 | — | — | WO | disclosed |
| US-9045516-B2 | Synthetic ligands for the differentiation of closely related toxins and pathogens | UNIVERSITY OF CINCINNATI | 2015-06-02 | — | — | US | disclosed |
| US-20090042816-A1 | Synthetic Ligands For The Differentiation Of Closely Related Toxins And Pathogens | UNIVERSITY OF CINCINNATI | 2009-02-12 | — | — | US | disclosed |
| US-7169940-B1 | Compounds and pharmaceutical compositions comprising same | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2007-01-30 | — | — | US | disclosed |
| WO-2000000514-A9 | SYNTHETIC SPIROKETAL PYRANES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INST (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | INF2, CPNE4, TEC | DUT 2132/4885ALDH1A1 1599/4885TSHR 3666/4885 |
| US-11220513-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | CROCC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KAT7 | DUT 2428/4885ALDH1A1 999/4885TSHR 2231/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | DUT 99/4885ALDH1A1 357/4885TSHR 778/4885 |
| US-20220071971-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, PKD1, PKD2 | DUT 3638/4885ALDH1A1 1333/4885TSHR 1576/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | DUT 3749/4885ALDH1A1 842/4885TSHR 1921/4885 |
| US-20090042816-A1 | Synthetic Ligands For The Differentiation Of Closely Related Toxins And Pathogens | ANTXR2, VIP, C3AR1 | DUT 3544/4885ALDH1A1 4038/4885TSHR 223/4885 |
| US-20150309022-A1 | Synthetic Ligands for the Differentiation of Closely Related Toxins and Pathogens | ANTXR2, VIP, C3AR1 | DUT 3544/4885ALDH1A1 4038/4885TSHR 223/4885 |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | NISCH, COASY, KLK7 | DUT 3686/4885ALDH1A1 1924/4885TSHR 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.